Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Obinutuzumab> ?p ?o }
Showing triples 1 to 95 of
95
with 100 triples per page.
- Obinutuzumab abstract "Obinutuzumab (called afutuzumab until 2009) is a humanized monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Biogen Idec, Chugai Pharmaceutical Co., and Hoffmann-La Roche Inc. for the treatment of lymphoma. It acts as an immunomodulator.Obinutuzumab targets CD20 and kills B cells. GlycArt's technology platform allowed control of protein glycosylation; the cells in which obinutuzumab is produced were engineered to overexpress two glycosylation enzymes, MGAT3 and Golgi mannosidase 2, which reduce the amount of fucose attached to the antibody, which in turn increases the antibody's ability to activate natural killer cells.Obinutuzumab was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients. Patients treated with Gazyva had median survival of 23 months before death or disease progression, compared with 11.1 months for patients on chemotherapy alone.".
- Obinutuzumab atcPrefix "L01".
- Obinutuzumab atcSuffix "XC15".
- Obinutuzumab casNumber "949142-50-1".
- Obinutuzumab fdaUniiCode "O43472U9X8".
- Obinutuzumab wikiPageID "19841411".
- Obinutuzumab wikiPageLength "5330".
- Obinutuzumab wikiPageOutDegree "26".
- Obinutuzumab wikiPageRevisionID "674378153".
- Obinutuzumab wikiPageWikiLink Afucosylated_monoclonal_antibodies.
- Obinutuzumab wikiPageWikiLink Atomic_mass_unit.
- Obinutuzumab wikiPageWikiLink B-cell_chronic_lymphocytic_leukemia.
- Obinutuzumab wikiPageWikiLink B_cell.
- Obinutuzumab wikiPageWikiLink B_cells.
- Obinutuzumab wikiPageWikiLink Biogen.
- Obinutuzumab wikiPageWikiLink Biogen_Idec.
- Obinutuzumab wikiPageWikiLink CD20.
- Obinutuzumab wikiPageWikiLink Category:Breakthrough_therapy.
- Obinutuzumab wikiPageWikiLink Category:Hoffmann-La_Roche.
- Obinutuzumab wikiPageWikiLink Chemotherapy.
- Obinutuzumab wikiPageWikiLink Chronic_lymphocytic_leukemia.
- Obinutuzumab wikiPageWikiLink Chugai_Pharmaceutical_Co..
- Obinutuzumab wikiPageWikiLink Food_and_Drug_Administration.
- Obinutuzumab wikiPageWikiLink Genetic_engineering.
- Obinutuzumab wikiPageWikiLink Glycosylation.
- Obinutuzumab wikiPageWikiLink Hoffmann-La_Roche.
- Obinutuzumab wikiPageWikiLink Immunomodulator.
- Obinutuzumab wikiPageWikiLink Immunotherapy.
- Obinutuzumab wikiPageWikiLink Industrial_fermentation.
- Obinutuzumab wikiPageWikiLink Intravenous_infusion.
- Obinutuzumab wikiPageWikiLink Intravenous_therapy.
- Obinutuzumab wikiPageWikiLink KDa.
- Obinutuzumab wikiPageWikiLink Lymphoma.
- Obinutuzumab wikiPageWikiLink MGAT3.
- Obinutuzumab wikiPageWikiLink Mannosidase.
- Obinutuzumab wikiPageWikiLink Monoclonal_antibodies.
- Obinutuzumab wikiPageWikiLink Monoclonal_antibody.
- Obinutuzumab wikiPageWikiLink NHS_England.
- Obinutuzumab wikiPageWikiLink NICE.
- Obinutuzumab wikiPageWikiLink National_Institute_for_Health_and_Care_Excellence.
- Obinutuzumab wikiPageWikiLink Natural_killer_cell.
- Obinutuzumab wikiPageWikiLink Natural_killer_cells.
- Obinutuzumab wikiPageWikiLinkText "Gazyva".
- Obinutuzumab wikiPageWikiLinkText "Obinutuzumab".
- Obinutuzumab wikiPageWikiLinkText "obinutuzumab".
- Obinutuzumab atcPrefix "L01".
- Obinutuzumab atcSuffix "XC15".
- Obinutuzumab c "6512".
- Obinutuzumab casNumber "949142".
- Obinutuzumab chemspiderid "NA".
- Obinutuzumab eliminationHalfLife "2453760.0".
- Obinutuzumab h "10060".
- Obinutuzumab hasPhotoCollection Obinutuzumab.
- Obinutuzumab kegg "D09321".
- Obinutuzumab legalUs "Rx-only".
- Obinutuzumab mabType "mab".
- Obinutuzumab molecularWeight "146.1".
- Obinutuzumab n "1712".
- Obinutuzumab o "2020".
- Obinutuzumab routesOfAdministration Intravenous_infusion.
- Obinutuzumab routesOfAdministration Intravenous_therapy.
- Obinutuzumab s "44".
- Obinutuzumab source "zu/o".
- Obinutuzumab target CD20.
- Obinutuzumab tradename "Gazyva, Gazyvaro".
- Obinutuzumab type "mab".
- Obinutuzumab unii "O43472U9X8".
- Obinutuzumab verifiedfields "changed".
- Obinutuzumab verifiedrevid "477243496".
- Obinutuzumab wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Obinutuzumab wikiPageUsesTemplate Template:Drugbox.
- Obinutuzumab wikiPageUsesTemplate Template:Immunosuppressants.
- Obinutuzumab wikiPageUsesTemplate Template:Main.
- Obinutuzumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Obinutuzumab wikiPageUsesTemplate Template:Monoclonals_for_tumors.
- Obinutuzumab wikiPageUsesTemplate Template:Reflist.
- Obinutuzumab subject Category:Breakthrough_therapy.
- Obinutuzumab subject Category:Hoffmann-La_Roche.
- Obinutuzumab hypernym Antibody.
- Obinutuzumab type ChemicalSubstance.
- Obinutuzumab type Drug.
- Obinutuzumab type ChemicalObject.
- Obinutuzumab type Thing.
- Obinutuzumab type Q8386.
- Obinutuzumab comment "Obinutuzumab (called afutuzumab until 2009) is a humanized monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Biogen Idec, Chugai Pharmaceutical Co., and Hoffmann-La Roche Inc. for the treatment of lymphoma. It acts as an immunomodulator.Obinutuzumab targets CD20 and kills B cells.".
- Obinutuzumab label "Obinutuzumab".
- Obinutuzumab sameAs أوبينوتوزوماب.
- Obinutuzumab sameAs Obinutuzumab.
- Obinutuzumab sameAs Afutuzumab.
- Obinutuzumab sameAs Obinutuzumabas.
- Obinutuzumab sameAs m.04q2lbw.
- Obinutuzumab sameAs Q389496.
- Obinutuzumab sameAs Q389496.
- Obinutuzumab wasDerivedFrom Obinutuzumab?oldid=674378153.
- Obinutuzumab isPrimaryTopicOf Obinutuzumab.